These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8210642)

  • 1. Susceptibility of human leukemia cells to allogeneic and autologous lymphokine-activated killer cells and its augmentation by exposure of leukemia target cells to cytotoxic drugs in vitro and in vivo.
    Teichmann JV; Ludwig WD; Thiel E
    Recent Results Cancer Res; 1993; 131():223-38. PubMed ID: 8210642
    [No Abstract]   [Full Text] [Related]  

  • 2. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of interleukin-2 activated MHC-nonrestricted lymphocytes in antileukemia activity and therapy.
    Lotzová E
    Leuk Lymphoma; 1992 May; 7(1-2):15-28. PubMed ID: 1472926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells.
    Ozdemir O; Savaşan S
    Clin Immunol; 2005 Jun; 115(3):240-9. PubMed ID: 15893691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
    Parrado A; Casares S; Rodríguez-Fernández JM
    Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2.
    Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W
    Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of autologous tumor cells in preventing lymphokine-activated killer cell induction in vitro.
    Slovin SF; Maguire HC; Mastrangelo MJ
    Cancer; 1990 Dec; 66(12):2541-6. PubMed ID: 2123415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.
    Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G
    Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
    Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
    Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cells in haematopoietic stem cell transplantation.
    Lowdell MW
    Transfus Med; 2003 Dec; 13(6):399-404. PubMed ID: 14651745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer.
    Zhukova OS; Gerasimova GK; Shubina IZh; Kiselevskii MV
    Bull Exp Biol Med; 2007 Aug; 144(2):231-4. PubMed ID: 18399288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural interleukin-2 and lymphokine activated killer cells in the treatment of neuroblastoma in vitro and in vivo.
    Berthold F; Himmelmann U; Pohl U
    Prog Clin Biol Res; 1991; 366():417-24. PubMed ID: 1906185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.